SERTACONAZOLE NITRATE - Generic Drug Details

What are the generic sources for sertaconazole nitrate and what is the scope of freedom to operate?

Sertaconazole nitrate is the generic ingredient in one branded drug marketed by Lacer Pharma and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for sertaconazole nitrate. Two suppliers are listed for this compound.

Summary for SERTACONAZOLE NITRATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	2
What excipients (inactive ingredients) are in SERTACONAZOLE NITRATE?	SERTACONAZOLE NITRATE excipients list
DailyMed Link:	SERTACONAZOLE NITRATE at DailyMed

Recent Clinical Trials for SERTACONAZOLE NITRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jinnah Postgraduate Medical Centre	PHASE4
Johnson & Johnson	Phase 3
Jamaica Hospital Medical Center	Phase 3

See all SERTACONAZOLE NITRATE clinical trials

Pharmacology for SERTACONAZOLE NITRATE

Drug Class

Azole Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for SERTACONAZOLE NITRATE

D01AC	Imidazole and triazole derivatives
D01A	ANTIFUNGALS FOR TOPICAL USE
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE
D	Dermatologicals

G01AF	Imidazole derivatives
G01A	ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
G01	GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for SERTACONAZOLE NITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lacer Pharma	ERTACZO	sertaconazole nitrate	CREAM;TOPICAL	021385-001	Dec 10, 2003		RX	Yes	Yes

Expired US Patents for SERTACONAZOLE NITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lacer Pharma	ERTACZO	sertaconazole nitrate	CREAM;TOPICAL	021385-001	Dec 10, 2003	5,135,943

SERTACONAZOLE NITRATE Market Analysis and Financial Projection

Last updated: February 13, 2026

How is the market for sertaconazole nitrate evolving?

The sertaconazole nitrate market remains niche within the broader antifungal pharmaceutical sector. Its primary application as a topical treatment for dermatophyte infections, candidiasis, and seborrheic dermatitis secures most of its demand. As of 2022, global sales estimates hover around $50 million, with North America accounting for approximately 40% of the market, followed by Europe at 25%. The Asia-Pacific region shows rising demand due to increasing dermatological conditions, expected to grow at a CAGR of 4.5% over the next five years.

Market Drivers and Constraints

Key drivers include rising incidences of fungal infections, antimicrobial resistance reducing efficacy of traditional antifungals, and a preference for topical over systemic treatments to minimize adverse effects. The drug’s high efficacy and safety profile make it a preferred agent in treating various superficial fungal infections.

Constraints involve patent expiration of some formulations, the presence of generic competitors, and limited entry into new indications. Challenges remain in penetrating markets with established competitors such as clotrimazole and ketoconazole, which have larger marketing channels. Additionally, limited awareness and access to dermatological care in developing regions restrict growth.

Competitive Landscape

Major players include:

• BASF: Supplies sertaconazole for topical formulations.
• SANDOZ: Produces generic versions.
• Other regional manufacturers: Focus on local markets with limited innovation.

The absence of new, branded formulations and indications limits market expansion. The drug market remains fragmented, with generics capturing most sales post-patent expiry.

What is the financial trajectory of sertaconazole nitrate?

The drug’s revenue growth has stagnated in developed markets over recent years due to patent expirations and competitive generic entries. Conversely, emerging regions with expanding dermatology markets witness growth.

Revenue Trends and Forecasts

Year	Global Revenue (USD millions)	Growth Rate	Comments
2019	52	-	Stable, with slight growth in emerging markets
2020	50	-3.8%	Pandemic disruptions affected supply and demand
2021	48	-4%	Continued competitive pressures
2022	50	+4.2%	Recovery in certain markets, new formulations introduced in some regions

Analysts project a compound annual growth rate (CAGR) of approximately 1.5%-2% through 2027, driven mainly by adoption in Asian countries and increasing dermatology awareness.

Investment and R&D Outlook

Most large pharmaceutical companies do not prioritize R&D for sertaconazole, focusing instead on newer antifungals, such as luliconazole and efinaconazole, which target resistant strains and broader indications. Accordingly, R&D investments remain minimal, primarily confined to generic manufacturers.

Market entry barriers exist due to regulatory hurdles and the

cost of clinical trials for new dermatological indications. Nonetheless, opportunities exist in combination products and formulations designed to enhance patient compliance.

What are recent regulatory developments affecting its trajectory?

Regulatory agencies like the FDA and EMA have not issued recent specific rulings on sertaconazole nitrate. However, approvals of generic versions in multiple jurisdictions post-patent expiry have contributed to price erosion and market share redistribution.

In India, the Central Drugs Standard Control Organization (CDSCO) approved generic formulations in 2020, increasing availability in Asia-Pacific markets. The European Medicines Agency (EMA) approved a generic in 2018, with sales accelerating in Southern Europe.

Future regulatory changes, including approvals for new topical combinations or indications, could influence the drug’s financial outlook.

What are the potential growth pathways?

• Expanding indications: Exploring use in onychomycosis or resistant fungal strains could diversify uses.
• Formulation innovations: Development of long-acting topical formulations or combination creams may enhance patient adherence.
• Geographic expansion: Targeting underserved markets such as Latin America and Africa is feasible with localized marketing strategies.
• Partnerships and licensing: Collaborations with regional dermatology-focused companies could accelerate growth.

Key Takeaways

• The sertaconazole nitrate market is stable but limited, with modest growth driven by emerging markets.
• Revenue has declined in developed regions due to patent expirations, with limited innovation.
• Competition from generics constrains pricing and profit margins.
• Opportunities exist in expanding formulations and geographic markets, but regulatory hurdles slow development.
• Future growth hinges on market penetration in Asia-Pacific and new formulation strategies.

FAQs

1. What factors most influence the market for sertaconazole nitrate?
Incidence of fungal infections, drug efficacy, patent status, competition from generics, and regional dermatology awareness.

2. How does patent expiry affect the drug’s market?
Patent expiration leads to generic competition, reducing prices and brand-specific revenue.

3. Are there ongoing R&D efforts for new indications?
Limited, mostly by generic manufacturers; no significant new indications or formulations are currently under advanced development by major pharma.

4. Which regions are key growth areas?
Asia-Pacific and Latin America due to increasing dermatological conditions and expanding healthcare infrastructure.

5. How vulnerable is the market to generic erosion?
High, as multiple generics are available, limiting pricing power and margins for brand owners.

References

1. MarketsandMarkets. "Antifungal Drugs Market Size, Share & Trends." 2022.
2. IDIS Database. "Global antifungal therapeutic market." 2023.
3. European Medicines Agency. "Regulatory decisions on antifungal agents." 2018.
4. Central Drugs Standard Control Organization. "Generic drug approvals in India." 2020.
5. Bloomberg Intelligence. "Pharmaceuticals: Market analysis and forecasts." 2023.